{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"075-360-284-347-508","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"075-360-284-347-508"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":6810,"type":"PATENT","title":"University of Western Australia","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1173,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8195,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Empty Search
Owner = University of Western Australia
More
Look for obvious synonyms.
Select All
Add to Collection.
Applicant=Univ Western Australia.
Choose 'More'
Look for any other obvious versions (Univ Western Australia Nedland)
Add to collection
Select UWA Collection
Select All
Expand Familes
Select All
Add to Collection
...................................Annie search ... 2nd time........
Search Applicants and Owners(us) = ' Univ* Weste* Aus*', ' Weste* Aus* Univ*' ,
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents = 1040
Empty Search
Owner = University of Western Australia
More
Look for obvious synonyms.
Select All
Add to Collection.
Applicant=Univ Western Australia.
Choose 'More'
Look for any other obvious versions (Univ Western Australia Nedland)
Add to collection
Select UWA Collection
Select All
Expand Familes
Select All
Add to Collection
...................................Annie search ... 2nd time........
Search Applicants and Owners(us) = ' Univ* Weste* Aus*', ' Weste* Aus* Univ*' ,
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents = 1040
(i) an antisense oligonucleotide of 24 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−06+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(ii) an antisense oligonucleotide of 21 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A (−03+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(iii) an antisense oligonucleotide of 25 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−07+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(iv) an antisense oligonucleotide of 20 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−06+14), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
or a pharmaceutically acceptable salt thereof,\nthereby treating the patient."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antisense oligonucleotide is administered intravenously."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 8 skipping, comprising administering to the patient an antisense oligonucleotide selected from the group consisting of:\n
(i) an antisense oligonucleotide of 24 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG UAA (SEQ ID NO: 1), in which the uracil bases are thymine bases and wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide;\n
(ii) an antisense oligonucleotide of 21 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG (SEQ ID NO: 2), in which the uracil bases are thymine bases and wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide;\n
(iii) an antisense oligonucleotide of 25 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG UAA G (SEQ ID NO: 3), in which the uracil bases are thymine bases and wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide;\n
(iv) an antisense oligonucleotide of 20 bases comprising the base sequence GGU GGU AUC AAC AUC UGU AA (SEQ ID NO: 4), in which the uracil bases are thymine bases and wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide;\n
or a pharmaceutically acceptable salt thereof,\nthereby treating the patient."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the antisense oligonucleotide is administered intravenously."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 8 skipping, comprising administering to the patient a pharmaceutical composition comprising:\n
(a) an antisense oligonucleotide selected from the group consisting of:\n\n(i) an antisense oligonucleotide of 24 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG UAA (SEQ ID NO: 1), in which the uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain;\n(ii) an antisense oligonucleotide of 21 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG (SEQ ID NO: 2), in which the uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain;\n(iii) an antisense oligonucleotide of 25 bases comprising the base sequence GAU AGG UGG UAU CAA CAU CUG UAA G (SEQ ID NO: 3), in which the uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain;\n(iv) an antisense oligonucleotide of 20 bases comprising the base sequence GGU GGU AUC AAC AUC UGU AA (SEQ ID NO: 4), in which the uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain;\nor a pharmaceutically acceptable salt thereof; and\n
(b) a pharmaceutically acceptable carrier,\nthereby treating the patient."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the antisense oligonucleotide is administered intravenously."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method for restoring an mRNA reading frame to induce dystrophin protein production in a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 8 skipping, comprising administering to the patient an antisense oligonucleotide selected from the group consisting of:\n
(i) an antisense oligonucleotide of 24 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−06+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(ii) an antisense oligonucleotide of 21 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A (−03+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(iii) an antisense oligonucleotide of 25 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−07+18), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
(iv) an antisense oligonucleotide of 20 bases in length 100% complementary to a target region of exon 8 of the human dystrophin pre-mRNA, wherein the target region is annealing site H8A(−06+14), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 8 skipping;\n
or a pharmaceutically acceptable salt thereof,\nthereby restoring the mRNA reading frame to induce dystrophin protein production in the patient."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the antisense oligonucleotide is chemically linked to a polyethylene glycol chain."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the antisense oligonucleotide is administered intravenously."],"number":14,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}